We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $141.29 in the latest trading session, marking a -2.15% move from the prior day. This change lagged the S&P 500's 1.36% loss on the day. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.
Shares of the HIV and hepatitis C drugmaker have depreciated by 7% over the course of the past month, underperforming the Medical sector's loss of 5.66%, and the S&P 500's loss of 1.76%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is predicted to post an EPS of $1.86, indicating a 2.76% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.86 billion, indicating a 2.93% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.66 per share and a revenue of $30.18 billion, signifying shifts of +6.26% and +2.49%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.3% downward. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is presently being traded at a Forward P/E ratio of 16.68. This indicates a discount in contrast to its industry's Forward P/E of 18.83.
Investors should also note that GILD has a PEG ratio of 1.89 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.55.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Gilead Sciences (GILD - Free Report) closed at $141.29 in the latest trading session, marking a -2.15% move from the prior day. This change lagged the S&P 500's 1.36% loss on the day. Elsewhere, the Dow saw a downswing of 1.64%, while the tech-heavy Nasdaq depreciated by 1.46%.
Shares of the HIV and hepatitis C drugmaker have depreciated by 7% over the course of the past month, underperforming the Medical sector's loss of 5.66%, and the S&P 500's loss of 1.76%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is predicted to post an EPS of $1.86, indicating a 2.76% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.86 billion, indicating a 2.93% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.66 per share and a revenue of $30.18 billion, signifying shifts of +6.26% and +2.49%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.3% downward. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is presently being traded at a Forward P/E ratio of 16.68. This indicates a discount in contrast to its industry's Forward P/E of 18.83.
Investors should also note that GILD has a PEG ratio of 1.89 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.55.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.